Analgesia after Epidural Dexamethasone is Further Enhanced by IV Dipyrone, but Not IV Parecoxibe Following Minor Orthopedic Surgery

Gabriela R Lauretti, Claudia CF Righeti, and Antonio T Kitayama

Background:

Epidural administration of dexamethasone has been suggested for pain control after minor orthopedic surgery. This study was conducted to assess its efficacy after such surgery, combined or not to IV dipyrone, IV parecoxibe or their combination.

Methods:

91 patients were randomly assigned to seven groups. Patients were submitted to spinal bupivacaine anesthesia combined to epidural administration of either 10 ml saline or 10 mg dexamethasone diluted to 10-ml volume. Patients also received 10 ml IV saline or 1 gr dipyrone and/or 40 mg parecoxibe diluted to 10 ml with saline. Control group (CG) received epidural and IV saline. Dexamethasone group (DexG) received epidural dexamethasone and IV saline. Dexamethasone group (DipG) received epidural saline and IV dipyrone. Dex-Dip G received epidural dexamethasone and IV dipyrone. Parecoxibe group (ParG) received epidural saline and IV parecoxibe. Dex-ParG received epidural dexamethasone and IV parecoxibe. Finally, Dex-Dip-ParG received epidural dexamethasone and IV dipyrone plus IV parecoxibe.

Results:

The CG expressed 4h of analgesia and sooner requested pain killer. DexG was similar to DipG or ParG or Dex-ParG (7-hours), and they requested less ketoprofen compared to the CG (P < 0.05). However, the Dex-DipG and the Dex-Dip-ParG resulted in longer time to demand pain killer (17-hours) and less ketoprofen consumption in 24-hours (P < 0.002). Adverse effects were similar among groups.

Conclusions:

The analgesia secondary to epidural dexamethasone was enhanced by IV dipyrone, while no effects were observed by the addition of IV parecoxibe. (Korean J Pain 2014; 27: 345-352)

Key Words:
epidural dexamethasone, orthopedic surgery, postoperative pain, IV dipyrone, IV parecoxibe.
INTRODUCTION

As examples of efficacy, a single-dose combination of methylprednisolone and etoricoxib was demonstrated to reduce both postoperative pain and nausea following laparoscopic cholecystectomy [1], an example of visceral nociceptive pain; and preoperative treatment with dexamethasone and dipyrone but not dipyrone alone prevented sensory hypersensitivity following third molar extraction [2], an example of neuropathic pain.

Minor orthopedic procedures are examples of somatic nociceptive pain and are frequently scheduled as outpatient surgery. Therefore, it is commanding that the patient can get home in the same day with efficient analgesia along with no adverse effects, and non-opioid drugs combinations represent a good alternative for safety. Because epidural dexamethasone has been previously demonstrated to be competent after orthopedic surgeries [3–5] or back pain [6], we evaluated different intravenous (IV) non-narcotic analgesics combined to epidural dexamethasone under spinal bupivacaine anesthesia in patients scheduled to minor orthopedic surgeries.

MATERIALS AND METHODS

The Ethical Committee of The Teaching Hospital of the School of Medicine of Ribeirão Preto from the University of São Paulo approved this protocol (Protocol number 3420/2005). After gaining the subjects approval and written informed consent, 91 ASA status I and II patients undergoing minor orthopedic surgery were computer randomized to one of seven groups (n = 13) and prospectively evaluated using a placebo-controlled double-blind design to examine analgesia and perioperative adverse effects. The concept of a visual analogue scale (VAS), which consisted of a 10-cm line with 0 equaling “no pain at all” and 10 equaling “the worst possible pain” was introduced to the subjects before surgery. Exclusion criteria included diabetes and psychiatric disease.

The patients were premedicated with 0.05–0.1 mg/kg IV midazolam immediately before going to the operating room (OR). Hydration consisted of a rapid infusion of 10 ml/kg lactate solution before surgery and 10 ml/kg/hour after spinal anesthesia. Combined spinal/epidural anesthesia was performed in the operating room at the L2–L3 (epidural) and L3–L4 (spinal) interspaces in the sitting position. One anesthesiologist prepared the test drugs, while a different one performed the spinal/epidural punctures. The epidural test drug was either saline or 10 mg dexamethasone diluted in saline (to a final volume of 10 ml) injected as a bolus. Just after epidural drugs administration, spinal bupivacaine was injected at 1 ml per 7 seconds through a 25-gauge spinal needle (Table 1). All patients received 15 mg hyperbaric bupivacaine. Patients were placed supine immediately after the spinal/epidural punctures. Subsequently, the IV test drugs (1 gr dipyrone or 40 mg parecoxibe) administered are described in Table 1, and were also injected blindly, diluted in saline to a final 10-ml volume.

Patients were located at seven groups: 1) Patients from the Control group (CG) received epidural and IV saline as the test drugs, 2) Patients from the Dexamethasone group (DexG) received epidural dexamethasone and IV saline, 3) Patients from the Dipyrone group (DipG) received epidural dipyrone and IV saline, 4) Patients from the Dexamethasone-dipyrone group (Dex-DipG) received epidural dexamethasone and IV dipyrone, 5) Patients from the Parecoxibe group (ParG) received epidural parecoxibe and IV saline, 6) Patients from the Dexamethasone-parecoxibe group (Dex-ParG) received epidural dexamethasone and IV parecoxibe, 7) Patients from the Dexamethasone-dipyrone-parecoxibe group (Dex-Dip-ParG) received epidural dexamethasone, epidural dipyrone, and IV parecoxibe.

| Study Groups (All Patients Received Simultaneous 15 mg Bupivacaine Spinal Anesthesia) |
|---------------------------------------------------------------|
| **Epidural (10 ml)** | **Intravenous (10 ml)** |
| CG                | Saline (10 ml) | Saline (10 ml) |
| DexG              | 10 mg dexamethasone diluted in saline (final volume 10 ml) | Saline (10 ml) |
| DipG              | Saline (10 ml) | 1 gr dipyrone diluted in saline (final volume 10 ml) |
| Dex-DipG          | 10 mg dexamethasone diluted in saline (final volume 10 ml) | 1 gr dipyrone diluted in saline (final volume 10 ml) |
| ParG              | Saline (10 ml) | 40 mg parecoxibe diluted in saline (final volume 10 ml) |
| Dex-ParG          | 10 mg dexamethasone diluted in saline (final volume 10 ml) | 40 mg parecoxibe diluted in saline (final volume 10 ml) |
| Dex-Dip-ParG      | 10 mg dexamethasone diluted in saline (final volume 10 ml) | 1 gr dipyrone + 40 mg parecoxibe diluted in saline (final volume 10 ml) |

CG: control group, DexG: dexamethasone group, Dex-DipG: dexamethasone-dipyrone group, ParG: parecoxibe group, Dex-ParG: dexamethasone-parecoxibe group, Dex-Dip-ParG: dexamethasone-dipyrone-parecoxibe group.
saline and IV dipyrone, 4) Patients from the Dexamethasone–Dipyrone group (Dex–DipG) received epidural dexamethasone and IV dipyrone, 5) Patients from the Parecoxibe group (ParG) received epidural saline and IV parecoxibe, 6) Patients from the Dexamethasone Parecoxibe group (Dex–ParG) received epidural dexamethasone and IV parecoxibe, 7) Finally, patients from the Dex–Dip–ParG received epidural dexamethasone and IV combination of dipyrone plus parecoxibe. Further IV midazolam was given consistent with the anesthesiologist’s perception, based on patient’s wellbeing.

Intraoperative sensory loss valuation comprised the pinprick test at 5– and 10-min after the spinal anesthesia. Blood pressure was supervised non-invasively every 5 min all over surgery, and heart rate and oxyhemoglobin saturation were continuously overseen during the progression of the surgery. A decrease in mean arterial pressure greater than 15% below pre-anesthetic baseline was treated with incremental doses of ephedrine. Diminutions in heart rate below 50 bpm were handled with atropine, 0.25 mg IV, along with the anesthesiologist’s judgment. Intraoperative nausea was scored by the patient using the 10 cm VAS. The numbers of patients with nausea (of any degree) or vomiting at any intraoperative time were noted. Nausea greater than 2/10 at any time or vomiting during the study was handled with 8 mg IV ondansetron, if necessary. For patients with more than one episode of nausea, the VAS scores were averaged.

Postoperative evaluation included duration of motor block (determined from spinal anesthesia until time to reach a Bromage 2 score [7], pain scores, the occurrence of fever, wound infection and wound dehiscence, heal at the 7th day, or any other adverse effects. Nausea and vomiting were assessed intraoperatively and at 24–hour after the spinal puncture by the same anesthesiologist, eyeless to the treatment.

Pain was assessed at the time of first rescue analgesic and 24 hours after the spinal puncture by the anesthesiologist who was blind to the study conduction, and patients were allowed to receive rescue analgesics at the time requested as IV 50 mg ketoprofen was accessible at 4–hour-interval. The duration of successful analgesia was determined as the time from the epidural puncture to the patient’s first demand for analgesics either in the recovery room or infirmary, documented in minutes. The VAS at the time of first rescue analgesic was measured by means of 10-cm VAS. The 24–hour VAS pain score and VAS for nausea signified the patient’s overall sense of the 24–hour following epidural injection.

1. Statistical analysis

The power of the study was based upon pilot data. We hypothesized that 10 mg of epidural dexamethasone would amplify the time to first rescue analgesic by 100% compared to the CG in the population considered, and estimated that the addition of IV drug would further increase the time to first rescue analgesic by 20% compared to the Dexamethasone group. If a standard deviation was estimated, an 80% and an alpha value of 0.05, these suppositions would require at least 10 patients in each group.

The normality of the distributions was judged using the Shapiro–Wilk’s test. Groups were compared for demographic data (i.e., age, weight and height) and duration of surgery by one-way ANOVA. Incidence of adverse events, gender, ASA status and adjuvant drug use were compared among groups by Chi-square corrected for multiple comparisons, \( P < 0.007 \) was considered significant (i.e., 0.05 divided by the number of groups). Blood pressure, heart rate, level of anesthesia (by pinprick test) and VAS scores were compared among groups by two-way ANOVA for repeated measures. Tukey analysis was utilized to decrease the probability of type I error. The time to first rescue analgesics and the analgesic consumption (mg) in 24 hours were compared using the Kruskal–Wallis on ranks followed by the Student–Newmans–Keuls test. \( P < 0.05 \) was considered significant, Data are expressed as means ± SD, unless otherwise identified.

**RESULTS**

Eighty eight patients were evaluated. One patient from the CG, one from the DipG and one from the ParG were excluded due to incomplete data compilation. All patients underwent minor orthopedic surgeries (\( P > 0.05 \); Table 2). The groups showed no disparities regarding ASA status, gender, age, weight or height (\( P > 0.05 \), Table 3). The sensory level to pinprick at 5– and 10-min after the spinal puncture (\( P > 0.05 \); Table 4), surgical and anesthetic time, and intraoperative ephedrine consumption were similar among the groups (\( P > 0.05 \); Table 5). The intraoperative midazolam administration was also similar among the groups (2.5–5 mg, \( P > 0.05 \), data not shown).


Table 2. Number of Patients Submitted to Different Surgical Procedures in the Groups

|                        | Arthroscopic knee ligament reconstruction | Tibial osteosynthesis |
|------------------------|------------------------------------------|-----------------------|
| CG                     | 6                                        | 4                     |
| DexG                   | 5                                        | 5                     |
| DipG                   | 7                                        | 3                     |
| Dex-DipG               | 5                                        | 6                     |
| ParG                   | 6                                        | 4                     |
| Dex-ParG               | 7                                        | 4                     |
| Dex-Dip-ParG           | 7                                        | 5                     |

P > 0.05. CG: control group, DipG: dipyrone group, DexG: dexamethasone group, Dex-DipG: dexamethasone-dipyrone group, ParG: parecoxib group, Dex-ParG: dexamethasone-parecoxibe group, Dex-Dip-ParG: dexamethasone-dipyrone-parecoxibe group.

Table 3. Demographic Data

|                        | ASA status (I/II) | Gender M/F | Weight* (kg) | Age* (years) | Height* (cm) |
|------------------------|------------------|------------|--------------|--------------|--------------|
| CG                     | 9/3              | 10/2       | 79 ± 9       | 35 ± 8       | 171 ± 5      |
| DexG                   | 10/3             | 8/5        | 72 ± 9       | 32 ± 8       | 169 ± 7      |
| DipG                   | 9/3              | 9/3        | 78 ± 8       | 30 ± 12      | 173 ± 9      |
| Dex-DipG               | 9/4              | 10/3       | 75 ± 12      | 35 ± 8       | 169 ± 9      |
| ParG                   | 10/2             | 8/4        | 76 ± 19      | 33 ± 10      | 171 ± 7      |
| Dex-ParG               | 11/2             | 9/4        | 79 ± 9       | 38 ± 11      | 170 ± 9      |
| Dex-Dip-ParG           | 11/2             | 9/4        | 72 ± 9       | 35 ± 12      | 172 ± 7      |

CG: control group, DipG: dipyrone group, DexG: dexamethasone group, Dex-DipG: dexamethasone-dipyrone group, ParG: parecoxib group, Dex-ParG: dexamethasone-parecoxibe group, Dex-Dip-ParG: dexamethasone-dipyrone-parecoxibe group. M: male; F: female.

Table 4. Sensorial Level Evaluated by Pinprick at 5- and 10-Min after the Spinal Puncture. The Thoracic Dermathomes Varied from T1 to T12

|                        | Thoracic sensorial level in 5-min* | Thoracic sensorial level in 10-min (T)* |
|------------------------|-----------------------------------|----------------------------------------|
| CG                     | 9 (9–11)                          | 9 (9–10)                               |
| DexG                   | 10 (10–12)                        | 9 (8–10)                               |
| DipG                   | 9 (9–11)                          | 8 (8–10)                               |
| Dex-Dip G              | 10 (10–11)                        | 8 (8–10)                               |
| ParG                   | 9 (9–12)                          | 8 (8–10)                               |
| Dex-ParG               | 10 (10–12)                        | 9 (9–10)                               |
| Dex-Dip-ParG           | 10 (10–11)                        | 8 (8–9)                                |

P > 0.05. CG: control group, DipG: dipyrone group, DexG: dexamethasone group, Dex-DipG: dexamethasone-dipyrone group, ParG: parecoxib group, Dex-ParG: dexamethasone-parecoxibe group, Dex-Dip-ParG: dexamethasone-dipyrone-parecoxibe group. *Data expressed as median (25%–75% confident interval).

Table 5. Surgical and Anesthetic Time, Intraoperative Ephedrine Consumption

|                        | Surgical time (minutes)* | Time to Bromage 2° (minutes)* | Ephedrine consumption (mg)* |
|------------------------|--------------------------|-------------------------------|-----------------------------|
| CG                     | 137 ± 34                 | 166 ± 40                      | 6 ± 8                       |
| DexG                   | 130 ± 60                 | 164 ± 29                      | 9 ± 13                      |
| DipG                   | 126 ± 47                 | 178 ± 37                      | 9 ± 11                      |
| Dex-DipG               | 134 ± 50                 | 179 ± 26                      | 13 ± 10                     |
| ParG                   | 135 ± 60                 | 168 ± 32                      | 8 ± 13                      |
| Dex-ParG               | 129 ± 24                 | 186 ± 26                      | 13 ± 10                     |
| Dex-Dip-ParG           | 132 ± 51                 | 176 ± 32                      | 8 ± 13                      |

P > 0.05. CG: control group, DipG: dipyrone group, DexG: dexamethasone group, Dex-DipG: dexamethasone-dipyrone group, ParG: parecoxib group, Dex-ParG: dexamethasone-parecoxibe group, Dex-Dip-ParG: dexamethasone-dipyrone-parecoxibe group. *Data expressed as mean ± SD.

The postoperative data are exposed in Table 6. The pain VAS score at the time of first rescue analgesic mediation was analogous among all groups (P > 0.05). The CG had the shorter period of time for first rescue analgesic since the epidural puncture (4 hours). The time to first rescue analgesic was similar to the DexG, DipG, ParG and Dex–ParG (7 hours; P > 0.05), even though longer when compared to the CG (P < 0.05), and shorter when compared to the Dex–DipG and to the Dex–Dip–ParG (17 hours; P < 0.05), which were similar between them (P > 0.05). The number of rescue injections of IV ketoprofen (50 mg) in 24-hour evaluation was greater for the CG, compared to the others (P < 0.05). The analgesic consumption was similar to the DexG, DipG, ParG and Dex–ParG (P > 0.05), although greater when compared to the Dex–DipG and Dex–Dip–ParG (P < 0.05), which was similar between them (P > 0.05). The overall 24-hour pain falling was similar among all groups (P > 0.05).

The occurrence of perioperative adverse effects in 24-hour observation was similar among groups (P > 0.05; Table 7). The occurrence of fever, wound infection and
Table 6. Postoperative Pain Evaluation

|                | Time to first rescue analgesic (minutes)* | Initial VAS (cm) | Number of IV Ketoprofen administration in 24 hours † | 24-hour VAS (cm)* |
|----------------|------------------------------------------|-----------------|-----------------------------------------------------|------------------|
| CG             | 239 ± 58                                  | 6 ± 2           | 3 (3−4)                                             | 2 ± 2            |
| DexG           | 446 ± 62                                  | 6 ± 3           | 2 (2−3)                                             | 1.6 ± 1          |
| DipG           | 424 ± 53                                  | 6 ± 2           | 2 (2−3)                                             | 1.8 ± 1          |
| Dex-DipG       | 1020 ± 153                                | 5 ± 2           | 1 (1−2)                                             | 1.2 ± 1          |
| ParG           | 488 ± 54                                  | 6 ± 2           | 2 (2−3)                                             | 1.8 ± 1          |
| Dex-ParG       | 413 ± 80                                  | 6 ± 3           | 2 (2−3)                                             | 1.2 ± 1          |
| Dex-Dip-ParG   | 1108 ± 180                                | 5 ± 3           | 2 (1−2)                                             | 1.3 ± 1          |

CG: control group, DipG: dipyrone group, DexG: dexamethasone group, Dex-DipG: dexamethasone-dipyrone group, ParG: parecoxib group, Dex-ParG: dexamethasone-parecoxib group, Dex-Dip-ParG: dexamethasone-dipyrone-parecoxibe group. †: CG< DexG (P < 0.05) = DipG = ParG = Dex-ParG < Dex-DipG = Dex-Dip-ParG (P < 0.002). *Data expressed as mean ± SD. †Data expressed as median (25%−75% confident interval).

Table 7. Incidence of Adverse Effects during the Postoperative period. Data Reveals the Number of Patient that had Each Described Adverse Effect in Each Group

|                | Nausea | Vomiting | Headache |
|----------------|--------|----------|----------|
| CG             | 0      | 0        | 1        |
| DexG           | 1      | 0        | 0        |
| DipG           | 0      | 0        | 0        |
| Dex-DipG       | 1      | 1        | 0        |
| ParG           | 1      | 0        | 0        |
| Dex-ParG       | 0      | 0        | 0        |
| Dex-Dip-ParG   | 1      | 0        | 0        |

P > 0.05. CG: control group, DipG: dipyrone group, DexG: dexamethasone group, Dex-DipG: dexamethasone-dipyrone group, ParG: parecoxib group, Dex-ParG: dexamethasone-parecoxib group, Dex-Dip-ParG: dexamethasone-dipyrone-parecoxibe group.

wound dehiscence was similar among all groups. In fact none of these adverse effects occurred. Healing at the 7th postoperative day post-surgery was similar among groups. Postoperatively, one patient from each of the following groups: DexG, Dex-DipG, ParG, Dex-Dip-ParG had complained of postoperative nausea, however only the patient from the ParG and the one from the Dex-DipG had vomited once after dinner; though no pharmacological treatment was mandatory. One patient from the CG and one from the ParG complained of transient headache. These patients preferred only to rest because of history of past headache. No other adverse effects were perceived.

DISCUSSION

We revealed that epidural 10 mg dexamethasone resulted in similar analgesia to either IV 1 gr dipyrone alone or to IV 40 mg parecoxibe alone (7 hours); while the association of epidural dexamethasone and IV dipyrone resulted in enhanced analgesia (17 hours) in the population studied. Intriguingly, the association of IV parecoxibe to epidural dexamethasone had no gain to either drug alone in this current evaluation.

The reason for the epidural route of dexamethasone administration instead of the IV was based in its historically positive effect in orthopedics [4-8]. It may be acting at spinal sites by inducing the synthesis of the phospholipase-A2 inhibitory protein lipocortin [9]. The inhibition of phospholipase A2 reduces prostaglandin and leukotriene synthesis, suppressing hyperalgesia associated to acute nociception during surgery. In addition, high levels of glucocorticoid receptor and mineralocorticoid receptor are co-localized in the substantia gelatinosa [10], suggesting that the pain pathways are strongly regulated by these receptors. Dexamethasone was also shown to down-regulate cyclooxygenase (COX)-2 mRNA, an important step for its anti-inflammatory action [11]; to inhibit the Nox- (a subunit component of NADPH oxidase) dependent reactive oxygen production, to inhibit oxide nitric release and finally inhibit the inflammatory reaction of activated microglial cells [12], to up regulate the N-methyl-D-aspartate receptor subunit 2B expression in the spinal...
dorsal horn [13] and to induce inhibition of glutamatergic transmission [14].

Indeed, fifty years have elapsed since the first publication of epidural dexamethasone for pain relief [8], and it has been used for orthopedics [4–7], for other surgical procedures [15–18] or pain [8,19] procedures. The non-particulate dexamethasone is the routine steroid used in our Pain Center for the past 25 years. Recently it has been demonstrated to be no inferior compared to particulate steroids [20]. In fact, dexamethasone has particles significantly smaller than red blood cells, with the least tendency to aggregation, and the lowest density and reduced the risk of embolic infarcts. These characteristics transform this drug as one of the safest for epidural administration [21]. The epidural dexamethasone dose varied in the literature from 0.1 mg/kg in children 15 to 10 mg in adults [6,18].

In our study, the decision for the association of epidural dexamethasone to spinal bupivacaine was based on previous positive effects in different postoperative types of pain [4–7,15–18]. Postoperative pain can normally be classified as nociceptive somatic, 2) nociceptive visceral, and 3) neuropathic pain. As examples, steroids have been previously demonstrated to benefit the neuropathic pain [5–8] and the nociceptive visceral pain [15–18]. Another point in favor to the decision of epidural dexamethasone would be its benefit in reducing backache after lumbar epidural anesthesia [22] and its protective in vitro effect over spinal bupivacaine neurotoxicity [23].

Customarily we combine epidural dexamethasone to spinal opioid analgesia for upgrading perioperative analgesia following major orthopedic operations. It was suggested that epidural bupivacaine–dexamethasone had almost the same analgesic potency as bupivacaine–fentanyl with opioid-sparing [15,16], produced antiemetic effects [16], decreased pain in the short term, abbreviated the length of stay after lumbar spinal surgery [7] and improved epidural methadone analgesia [19]. For the reason that intrathecal opioids are not the more proper analgesics for outpatient surgeries, other picks could be IV parecoxibe or IV dipyrone.

In this actual study, we evaluated postoperative pain after minor orthopedic surgeries, which is a representative of pure nociceptive somatic pain. Although dexamethasone’s efficacy after neuropathic and visceral pain has been previously demonstrated, we found no benefit after epidural dexamethasone alone (DexG) over either IV dipyrone (DipG) or IV parecoxibe alone (ParG), as all groups (DexG, DipG and ParG) had 7 hours of analgesia. In addition, the combination of epidural dexamethasone and IV parecoxibe (Dex–Dip–ParG) also resulted in 7 hours of postoperative analgesia, demonstrating no benefit of this association.

Parecoxibe is a specific COX–2 inhibitor [24], with no effect on the spinal N–methyl–D–aspartate receptor subunit 2B [25], conversely from dexamethasone10. IV parecoxibe has been previously demonstrated to improve IV dexamethasone analgesia in outpatient anterior cruciate ligament [26] and to result in 7 hours and 5 minutes of analgesia after orthopedic procedures [27], in accordance to our results (ParG). The lack of further analgesic effect of the Dex–ParG could be secondary to the minor tissue damage and smaller production of COX–2 in the patients evaluated, which would be even smaller secondarily to the inhibition of phospholipase A2 by dexamethasone, resulting in lesser central prostaglandin production. In this case, as central inhibition of COX is an important mechanism for IV parecoxibe [28], there would be not enough substrate for a clinical manifestation of analgesia. It seemed then, that dexamethasone and parecoxibe acted at the same final pain pathway, and were competitive. This competition would also occur at the periphery, as systemic effects of a single epidural dexamethasone injection could be demonstrated until the 7th day [29].

Interestingly, the association of epidural dexamethasone and IV dipyrone resulted in 17 hours of analgesia compared to 7 hours after each drug alone, suggesting a reciprocal enhancement of the final analgesic effect. In fact the results suggest at least summation of the analgesic effect of both drugs, exemplifying multimodal analgesia.

Active metabolites of dipyrone inhibit COX activity by sequestering radicals which initiate the catalytic activity of this enzyme or through the reduction of the oxidative states of the COX protein [30]. The active metabolites of the prodrug dipyrone could also inhibit COX–3 at the dorsal root ganglion [31] and represent a primary central mechanism by which dipyrone decrease pain and fever [32]. In addition, the metabolites arachidonoyl amides were positively tested for cannabis receptor binding type–1 and –2; suggesting that the endogenous cannabinoid system may play a role in the effects of dipyrone against pain [33].

Apart from COX–1, –2 and –3 inhibition and cannabis agonist, dipyrone causes antinociception by activating en-
dogenous opioidergic circuits along the descending pain control system [34]. In rats, responses of dorsal spinal wide-dynamic range neurons to mechanical noxious stimulation were strongly inhibited by intravenous dipyrone, an effect abolished by naloxone into the periaqueductal gray matter, into the nucleus raphe magnus or by direct application onto the spinal cord [34]. Lastly, but not less important, the suggested teleantagonism was also demonstrated after dipyrone. Intrathecal glutamate, N-methyl-D-aspartate, or prostaglandin E2 induced sensitization of the primary nociceptive neuron which was inhibited by peripheral dipyrone, a pharmacodynamic phenomenon referred to as teleantagonism [35].

Related to the adverse effects, none of the patients had serious complaints. In this study, dipyrone and dexamethasone were used as part of the protocol. One of the points addressed was that fever was an adverse effect evaluated in the postoperative period, however, dipyrone is well known thermo regulator and dexamethasone has been demonstrated to alleviate temperature elevation, an effect attributed to the decrease of interleukin-6 levels [36]. However, none patients felt fever. As part of exclusion criteria, diabetes patients did not participate due to the possibility of peripheral neuropathy and interference with results, although it has been recently demonstrated that epidural steroid efficacy was independent of the presence of type-2 diabetes [37]. Although flushing is more common with epidural dexamethasone and in women, it seems innocuous and self-limiting [38] and was not evaluated.

In conclusion, the analgesia secondary to epidural dexamethasone was exacerbated by IV dipyrone, while no effects were observed by the addition of IV parecoxibe suggesting that dexamethasone and parecoxibe may have acted at the same final pain pathway, and were competitive, while dipyrone mechanisms of action summated to dexamethasone’s ones.

ACKNOWLEDGEMENTS

The work was conducted by the Center for Pain Treatment/done of the Teaching Hospital of the School of Medicine of Ribeirão Preto—University of São Paulo, Brazil. The authors thank Professor of Orthopedics Cleber Antonio Jansen Paccola, MD (in memorian): responsible for the patients and for the healing evaluation at the 7th postoperative day.

REFERENCES

1. Gautam S, Agarwal A, Das PK, Agarwal A, Kumar S, Khuba S. Evaluation of the efficacy of methylprednisolone, etoricoxib and a combination of the two substances to attenuate postoperative pain and PONV in patients undergoing laparoscopic cholecystectomy: a prospective, randomized, placebostricted trial. Korean J Pain 2014; 27: 278–84.
2. Barron RP, Benoliel R, Zeltser R, Elav E, Nahlieli O, Gracely RH. Effect of dexamethasone and dipyrone on lingual and inferior alveolar nerve hypersensitivity following third molar extractions: preliminary report. J Orofac Pain 2004; 18: 62–8.
3. Ang ET, Goldfarb G, Kohn S, Galel C, Bex M, Deburge A, et al. Postoperative analgesia: epidural injection of dexamethasone sodium phosphate. Ann Fr Anesth Reanim 1988; 7: 289–93.
4. Rasmussen S, Krum–Mäller DS, Lauridsen LR, Jensen SE, Mandøe H, Gerill C, et al. Epidural steroid injection for herniated lumbar disc reduces neurological impairment and enhances recovery: a randomized study with two-year follow–up. Spine (Phila Pa 1976) 2008; 33: 2028–33.
5. Ranguis SC, Li D, Webster AC. Perioperative epidural steroids for lumbar spine surgery in degenerative spinal disease. A review. J Neurosurg Spine 2010; 13: 745–57.
6. Kim EJ, Moon JY, Park KS, Yoo da H, Kim YC, Sim WS, et al. Epidural steroid injection in korean pain physicians: a national survey. Korean J Pain 2014; 27: 35–42.
7. Bromage PR. A comparison of the hydrochloride and carbon dioxide salts of lidocaine and prilocaine in epidural analgesia. Acta Anaesthesiol Scand Suppl 1965: 16: 55–69.
8. Canale L. Epidural sacral administration of dexamethasone in lumbar sciatica, Gazz Med ital 1963: 122: 210–3.
9. Hirata F, Schillmann E, Venkatasubramanian K, Salomon D, Axelrod J. A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acad Sci USA 1980; 77: 2533–6.
10. Gu X, Peng L, Yang D, Ma Q, Zheng Y, Liu C, et al. The respective and interaction effects of spinal GFs and MRs on radicular pain induced by chronic compression of the dorsal root ganglion in the rat. Brain Res 2011; 1396: 88–95.
11. Inoue A, Ioma K, Morikas N, Kurnagi K, Hashimoto T, Hide I, et al. Interleukin–1beta induces substance P release from primary afferent neurons through the cyclooxygenase–2 system. J Neurochem 1999; 73: 2206–13.
12. Huo Y, Rangarajan P, Ling EA, Dheen ST. Dexamethasone inhibits the Nax–dependent ROS production via suppression of MKP–1–dependent MAPK pathways in activated microglia. BMC Neurosci 2011; 12: 49.
13. Ma ZL, Zhang W, Gu XP, Yang WS, Zeng YM. Effects of intrathecal injection of prednisolone acetate on expression of NR2B subunit and nNOS in spinal cord of rats after chronic
compression of dorsal root ganglia. Ann Clin Lab Sci 2007; 37: 349-55.
14. Wang J, Shen RY, Haj-Dahmane S. Endocannabinoids mediate the glucocorticoid-induced inhibition of excitatory synaptic transmission to dorsal raphe serotonin neurons. J Physiol 2012; 590: 5795-808.
15. Naghipour B, Aghamohamadi D, Azarfarin R, Mirinazhad M, Bilehrani E, Abbassali D, et al. Dexamethasone added to bupivacaine prolongs duration of epidural analgesia. Middle East J Anesthesiol 2013; 22: 53-7.
16. Thomas S, Beevi S. Epidural dexamethasone reduces postoperative pain and analgesic requirements. Can J Anaesth 2006; 53: 899-905.
17. Khafagy HF, Refaat AI, El-Sabae HH, Youssif MA. Efficacy of epidural dexamethasone in reducing postoperative pain, further enhanced by epidural dexamethasone. Br J Cancer 2013; 109: 62-6.
18. El-Yahchouchi C, Geske JR, Carter RE, Diehn FE, Wald JT, Murthy NS, et al. The noninferiority of the nonparticulate steroid dexamethasone vs the particulate steroids bupivacaine and tramadol in lumbar transforaminal epidural steroid injections. Pain Med 2008; 9: 227-34.
19. Gilbert BL, Yan PP, Yang CH, Tsai SC, Chung HS. Epidural dexamethasone reduces the incidence of backache after lumbar epidural anesthesia. Anesth Analg 1997; 84: 376-8.
20. Ma R, Wang X, Lu C, Li C, Cheng Y, Ding G, et al. Dexamethasone attenuated bupivacaine-induced neuron injury in vitro through a threonine-serine protein kinase B-dependent mechanism. Neuroscience 2010; 167: 329-42.
21. Gajraj NM. COX-2 inhibitors celecoxib and parecoxib: valuable options for postoperative pain management. Curr Top Med Chem 2007; 7: 235-49.
22. Zhou GB, Li HY, Ji JQ, Yu W, Ma WT. Analgesic effect of COX inhibitors and its mechanism in a rat model of neuropathic pain. Nan Fang Yi Ke Da Xue Xue Bao 2011; 31: 1764-6.
23. Dahl V, Spreng UJ, Waage M, Raeder JC. Short stay and less pain after ambulatory anterior cruciate ligament (ACL) repair: COX–2 inhibitor versus glucocorticoid versus both combined. Acta Anaesthesiol Scand 2012; 56: 95-101.
24. Desjardins RJ, Traylor L, Hubbard RC. Analgesic efficacy of preoperative parecoxib sodium in an orthopedic pain model. J Am Podiatr Med Assoc 2004; 94: 305-14.
25. Koppert W, Wehrfritz A, Körber N, Stütz R, Albrecht S, Schlüter J, et al. The cyclooxygenase isozyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans. Pain 2004; 108: 148-53.
26. Ma V, Shakir A. The impact of type 2 diabetes on numeric pain score reduction following cervical transforaminal epidural steroid injections. Skeletal Radiol 2013; 42: 1543-7.